ORDER A TEST Log In Contact Us

NEWS

Press Releases

Media Coverage

Additional Partnerships

Filter By
For all media inquiries, please contact media@tempus.com
  • 09/13/2024

    Tempus Announces Four Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2024

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced four abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2024, which convenes in Barcelona, Spain, from September 13-17, 2024.  "ESMO provides a great platform...

  • 09/12/2024

    Tempus Launches Beta Version of olivia, its AI-enabled Personal Health Concierge App for Patients

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the beta launch of a patient-facing app, olivia, an AI-enabled personal health concierge to empower individuals to holistically organize, manage, and proactively take control of their own health data. oli...

  • 09/04/2024

    Tempus Announces Real World Data Collaboration with BioNTech

    The strategic collaboration will leverage Tempus’ large multimodal datasets to enhance BioNTech’s next-generation oncology pipeline Tempus AI, Inc. (NASDAQ: TEM, “Tempus”), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a multi-year collaboration with BioNTech SE (Nasdaq: BNTX, “BioNTech”)...

  • 08/28/2024

    Tempus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4th, held in New York, NY. Tempus Founder and CEO, Eric Lefkofsky, will speak...

  • 08/08/2024

    NPJ Precision Oncology Publishes Tempus Study on Validation of its HLA-LOH Investigational Assay

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the validation study of its human leukocyte antigen (HLA) loss of heterozygosity (LOH) investigational assay has been published in npj Precision Oncology. Titled, “Detecting HLA loss of heterozygos...

  • 08/06/2024

    Tempus Reports Second Quarter 2024 Results

    CHICAGO, August 6, 2024 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter that ended June 30, 2024, and provided recent business highlights. Revenue increased 25% year-over-year to $166.0 million in the second quarter of 2024 Data licensing rev...

  • 08/01/2024

    Tempus Next Launches New Algorithm to Close Care Gaps in Guideline-Directed IHC Testing, Starting with HER2

    New RNA-based algorithm is now available with the xR assay

    Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced the launch of a new program specifically geared towards using algorithms to surface patients who are more likely to test positive for actionable biomarkers, and who should receive confirmatory testing in accordance with clinical guid...

  • 07/30/2024

    Tempus Announces Expanded Data and Sequencing Collaboration with Remix Therapeutics

    Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, announced an expanded collaboration with Remix Therapeutics, a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease. The collaboration between Remix and Tempus began with the licensing of specific, de-identified da...

  • 07/17/2024

    Tempus to Report Second Quarter 2024 Financial Results on August 6

    Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter on Tuesday, August 6, 2024. The company will hold the second quarter 2024 earnings conference call at 4:30 p.m. ET. The company’s quarterly earnings will be released the sa...

  • 07/16/2024

    Tempus Expands Immuno-Oncology Portfolio with Launch of AI-enabled, Multimodal Immune Profile Algorithmic Tests

    Available Today for Life Science Research Use Only Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that its multimodal immune profile score (IPS) algorithmic test is now available for research use only (RUO). IPS is the first offering of a larger immunotherapy-based portfolio bein...

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20